Sugi Predict

Sugi Predict / Compounds / SCHEMBL529351

SCHEMBL529351

SCHEMBL529351

O=C(O)c1cc2ccccc2nc1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 2/20 0.54
▸ ALDH1A1 P00352 4/20 0.52
▸ KDM4E B2RXH2 3/20 0.52
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ ATM Q13315 1/20 0.52
▸ MAPT P10636 2/20 0.51
▸ IKBKB O14920 1/20 0.50
▸ KEAP1 Q14145 1/20 0.50
▸ NFE2L2 Q16236 1/20 0.50
▸ RAB9A P51151 4/20 0.49
▸ NPC1 O15118 3/20 0.49
▸ KMT2A Q03164 4/20 0.49
▸ MGAM O43451 2/20 0.47
▸ IDO1 P14902 1/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ GAA P10253 1/20 0.47
▸ PPARD Q03181 1/20 0.45
▸ PPARA Q07869 1/20 0.45
▸ HPGD P15428 2/20 0.45
▸ TP53 P04637 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31105819 1.00 HTT (0.54) HTTALDH1A1KDM4ESMN1; SMN2ATM
Hydrochloric Acid SCHEMBL30026 0.98 HTT (0.52) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL30025 0.85 HTT (0.54) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL3705378 0.84 CNR2 (0.51) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL22983078 0.84 KMT2A (0.57) HTTALDH1A1KDM4ESMN1; SMN2MAPT
SCHEMBL29754608 0.84 IKBKB (0.67) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL3144090 0.84 KDM4E (0.55) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL31301 0.84 IKBKB (0.67) HTTALDH1A1KDM4ESMN1; SMN2ATM
SCHEMBL8807038 0.81 SMN1; SMN2 (0.56) ALDH1A1KDM4ESMN1; SMN2MAPTIKBKB
SCHEMBL5139948 0.81 HTT (0.60) HTTALDH1A1KDM4ESMN1; SMN2ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10401747-B1 Undercoat layer for imaging device XEROX CORPORATION (US) 2019-09-03 — — US claimed
CN-108484497-A A kind of synthetic method of 3- amino -7- chloroquinolines 苏州康润医药有限公司 2018-09-04 — — CN claimed
CN-100354265-C Pharmaceutical compounds XENOVA LTD (GB) 2007-12-12 — — CN claimed
EP-0934276-B1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LTD (GB) 2003-12-17 — — EP claimed
US-6218393-B1 IN THERAPY OF MULTIDRUG RESISTANT CANCERS, FOR EXAMPLE TO POTENTIATE CYTOTOXICITY OF CANCER DRUG XENOVA LIMITED (GB) 2001-04-17 — — US claimed
EP-0934276-A1 ANTHRANILIC ACID DERIVATIVES AS MULTI DRUG RESISTANCE MODULATORS XENOVA LIMITED (GB) 1999-08-11 — — EP claimed
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-06-26 — — US disclosed
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-05-13 — — US disclosed
CN-119874606-A Fused piperidinyl bicyclic and related compounds as modulators of C5a receptors 因弗拉克斯有限责任公司 2025-04-25 — — CN disclosed
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF CHENGDU KANGHONG PHARMACEUTICAL CO., LTD. (CN) 2025-04-10 — — US disclosed
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2025-04-08 — — US disclosed
CN-119585247-A Bicyclic heterocyclic amide inhibitors of nav1.8 for the treatment of pain 赛特温治疗公司 2025-03-07 — — CN disclosed
EP-4514789-A1 <SUP2/>? <SUB2/>?V?BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA1.8 FOR THE TREATMENT OF PAIN SiteOne Therapeutics, Inc. (US) 2025-03-05 — — EP disclosed
US-4705853-A ANTIHISTAMINES A. H. ROBINS COMPANY, INC. (US) 1987-11-10 — — US disclosed
US-4642343-A ANTIHISTAMINES A. H. ROBINS COMPANY, INCORPORATED (US) 1987-02-10 — — US disclosed
US-4604388-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof in a method of counteracting histamine A. H. ROBINS COMPANY, INCORPORATED (US) 1986-08-05 — — US disclosed
US-4592866-A Fused aromatic oxazepinones, thiazepinones, diazepinones and sulfur analogs thereof A. H. ROBINS COMPANY, INC. (US) 1986-06-03 — — US disclosed
EP-0090369-B1 SALICYLIC-ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS BASED ON THESE COMPOUNDS AND THEIR USE HOECHST AKTIENGESELLSCHAFT (DE) 1986-01-08 — — EP disclosed
US-4542127-A Antidiabetic salicylic acid derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1985-09-17 — — US disclosed
EP-0090369-A1 Salicylic-acid derivatives, process for their preparation, pharmaceutical preparations based on these compounds and their use HOECHST AKTIENGESELLSCHAFT (DE) 1983-10-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250205232-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1B, SLC26A4 HTT 4413/4885ALDH1A1 3524/4885KDM4E 2973/4885
US-20250115578-A1 AROMATIC FUSED RING NAV1.8 INHIBITOR, AND USE THEREOF SCN8A, SCN10A, SCN7A HTT 1076/4885ALDH1A1 3194/4885KDM4E 1058/4885
US-12297209-B2 Benzodiazepine derivatives as RSV inhibitors GABRA5, GABRA1, GABBR2 HTT 4383/4885ALDH1A1 621/4885KDM4E 1198/4885
US-12268694-B2 Combination pharmaceutical agents as RSV inhibitors ACE, ACE2, SPCS3 HTT 4145/4885ALDH1A1 4172/4885KDM4E 4059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.